A randomized, double-blind, placebo-controlled trial looked at patients with moderately severe Crohn’s disease who were in remission following steroid therapies. After a one-year follow-up, 47.5 percent of patients taking the probiotic and 53.2 percent in the placebo group had relapsed.
More Articles on Gastroenterology:
Carilion Clinic Gastroenterology Adds Four Specialists, Creates Fellowship Program
FDA Supports CT Colonography Screenings for Colon Cancer Prevention
Dr. Dennis Ng Joins Ferrell-Duncan Clinic as Gastroenterologist
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
